Rishabh Jain: What ALTAIR Teaches Us About ctDNA-Positive CRC
oncodaily - Rishabh Jain, Medical Oncologist at AIIMS, shared a post on X: “ctDNA-positive CRC after curative surgery sounds like the perfect place to intervene. But ALTAIR says: not so fast. Phase 3, double-blind […]
AI Summary: Coverage examines ALTAIR, a randomized phase‑3 trial testing post‑adjuvant chemotherapy for patients with resected colorectal cancer who are ctDNA‑positive. Experts dissect trial design, endpoints and implications for ctDNA‑guided treatment decisions, debating whether circulating tumor DNA should steer adjuvant therapy or remain an elegant biomarker with stubborn practical hurdles.
Related Stories
Adjuvant selpercatinib sharply cuts recurrence in RET‑fusion lung cancer / 13 days
DESTINY‑Lung03: T‑DXd shows activity in HER2 lung cancer; triplet stalls / 15 days
Single‑cycle pembrolizumab yields striking responses in dMMR colon cancer / 5 wks
Zanidatamab improves PFS over trastuzumab in HER2 GEA / 14 days
MAGE‑A4/A8 TCR bispecific T‑cell engager shows activity in solid tumors / 14 days
Teclistamab outperforms standard regimens in earlier-line relapsed myeloma / 16 days
Common asthma drug may overcome immunotherapy resistance in cancers / 25 days
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Clinical Trials, Neuroscience, Pediatric Oncology, Research Funding and look for the RSS link.
StackHealth Time Machine